Navigation Links
Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
Date:9/24/2010

TAMPA, Fla. Moffitt Cancer Center and GLG Pharma, LLC announced today that they have entered into a licensing agreement under which GLG Pharma, LLC has acquired the exclusive worldwide rights to a technology platform that includes a series of STAT3 inhibitors. Researchers at Moffitt discovered several classes of STAT3 inhibitors and evaluated their potential pre-clinically as novel anti-cancer drugs.

"Persistently activated STAT3 is a major contributor to human cancer; validating its usefulness as a cancer therapeutic target in collaboration with GLG will be a major milestone," said Said Sebti, Ph.D., chair of the Drug Discovery Department at Moffitt.

"One of several recent startup companies to be based on Moffitt technologies, GLG brings a highly experienced management team to the mix," said Ray Carpenter, senior licensing manager of The Office of Technology Management and Commercialization at Moffitt. "Their combined experience in taking technologies through clinical trials instills confidence that these technologies surrounding an important target, like the STAT3 pathway, is being placed in capable hands. Our office is delighted that GLG Pharma will move this technology from the laboratory to the clinic to improve patient care."

Under the license agreement, GLG Pharma has agreed to pay Moffitt when various commercialization milestones are reached, as well as make royalty payments on the sales of testing services and licensed products.

"This license agreement is the first key milestone established for the company in 2010," said Hector J. Gomez, M.D., Ph.D., CEO of GLG Pharma. "We believe that STAT3 inhibitors are the next generation of targeted therapies. They are anticipated to be very specific, have a broad spectrum of activity and are expected to be well tolerated and more efficacious compounds than current therapies."


'/>"/>

Contact: Michelle Foley
MFoley@Moffitt.org
813-745-1505
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Page: 1

Related medicine news :

1. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
2. Cancer-associated long noncoding RNA regulates pre-mRNA splicing
3. Declining breast cancer incidence in Canada with declining HRT usage
4. Sexual Problems May Arise After Breast Cancer
5. UCLA cancer researchers discover new signaling pathway that controls cell development and cancer
6. Patients with cancer who stop hospice care boost health-care costs
7. Mammograms Cut Breast Cancer Death Rates, But Only Modestly: Study
8. David Cheresh receives top award for cancer metastasis research
9. 70 percent of women likely to experience sexual problems after breast cancer
10. Physical limitations of breast cancer survivors
11. Synthetic lethality strategy improves molecularly targeted cancer therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)... ... 2016 , ... TherapySites, the leading website and ... Tennessee Counseling Association. This new relationship allows TherapySites to continue to extend ... exclusive benefits and promotional offers. , "TCA is extremely excited about this new ...
(Date:6/27/2016)... ... June 27, 2016 , ... TopConsumerReviews.com recently awarded their highest five-star rating to ... of individuals in the United States and Canada wear eyeglasses. Once considered to be ... vision and make a fashion statement. Even celebrities use glasses as a way of ...
(Date:6/26/2016)... ... June 26, 2016 , ... Pixel Film Studios Released ProSlice Levels, a ... can give their videos a whole new perspective by using the title layers ... Film Studios. , ProSlice Levels contains over 30 Different presets to choose from. ...
(Date:6/26/2016)... ... June 26, 2016 , ... ... have been diagnosed with endometriosis. These women need a treatment plan to not ... comprehensive approach that can help for preservation of fertility and ultimately achieving a ...
(Date:6/25/2016)... FL (PRWEB) , ... June 25, 2016 , ... The temporary closing of Bruton Memorial ... Plant City Observer , brings up a new, often overlooked aspect of head lice: the ... closing for fumigation is not a common occurrence, but a necessary one in the event ...
Breaking Medicine News(10 mins):
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... 2016 Research and Markets has announced ... Diagnostic Tests" report to their offering. ... The World Market for Companion Diagnostics covers ... Market analysis in the report includes the following: ... Diagnostic Kits) by Region (N. America, EU, ROW), 2015-2020 ...
(Date:6/24/2016)... , Belgium , June 24, ... VNRX), today announced the appointment of Dr. ... Directors as a Non-Executive Director, effective June 23, ... Audit, Compensation and Nominations and Governance Committees.  As ... Futcher will provide independent expertise and strategic counsel ...
Breaking Medicine Technology: